Yorktown Management & Research Company’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $375K | Sell |
17,300
-20,250
| -54% | -$439K | 0.36% | 124 |
|
|
2025
Q1 | $911K | Hold |
37,550
| – | – | 0.99% | 10 |
|
|
2024
Q4 | $784K | Hold |
37,550
| – | – | 0.75% | 26 |
|
|
2024
Q3 | $746K | Buy |
37,550
+17,300
| +85% | +$344K | 0.76% | 28 |
|
|
2024
Q2 | $314K | Sell |
20,250
-20,250
| -50% | -$314K | 0.34% | 145 |
|
|
2024
Q1 | $646K | Hold |
40,500
| – | – | 0.61% | 42 |
|
|
2023
Q4 | $681K | Hold |
40,500
| – | – | 0.71% | 36 |
|
|
2023
Q3 | $473K | Hold |
40,500
| – | – | 0.53% | 58 |
|
|
2023
Q2 | $544K | Sell |
40,500
-9,500
| -19% | -$128K | 0.59% | 55 |
|
|
2023
Q1 | $829K | Hold |
50,000
| – | – | 0.89% | 16 |
|
|
2022
Q4 | $930K | Hold |
50,000
| – | – | 1.14% | 11 |
|
|
2022
Q3 | $642K | Hold |
50,000
| – | – | 0.83% | 22 |
|
|
2022
Q2 | $351K | Buy |
+50,000
| New | +$351K | 0.45% | 99 |
|